Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.10 (
IKK
)
4,900
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Receptor-interacting protein (RIP) is a serine/threonine protein kinase that is critically involved in tumor necrosis factor receptor-1 (TNF-R1)-induced NF-kappa B activation. In a yeast two-hybrid screening for potential RIP-interacting proteins, we identified
ZIN
(zinc finger protein inhibiting NF-kappa B), a novel protein that specifically interacts with RIP.
ZIN
contains four RING-like zinc finger domains at the middle and a proline-rich domain at the C terminus. Overexpression of
ZIN
inhibits RIP-,
IKK
beta-, TNF-, and IL1-induced NF-kappa B activation in a dose-dependent manner in 293 cells. Domain mapping experiments indicate that the RING-like zinc finger domains of
ZIN
are required for its interaction with RIP and inhibition of RIP-mediated NF-kappa B activation. Overexpression of
ZIN
also potentiates RIP- and TNF-induced apoptosis. Moreover, immunofluorescent staining indicates that
ZIN
is a cytoplasmic protein and that it colocalizes with RIP. Our findings suggest that
ZIN
is an inhibitor of TNF- and IL1-induced NF-kappa B activation pathways.
...
PMID:A novel zinc finger protein interacts with receptor-interacting protein (RIP) and inhibits tumor necrosis factor (TNF)- and IL1-induced NF-kappa B activation. 1185 71